Literature DB >> 19058029

Consenting to uncertainty: challenges for informed consent to disease screening--a case study.

Mark Greene1, Suzanne M Smith.   

Abstract

This paper uses chronic beryllium disease as a case study to explore some of the challenges for decision-making and some of the problems for obtaining meaningful informed consent when the interpretation of screening results is complicated by their probabilistic nature and is clouded by empirical uncertainty. Although avoidance of further beryllium exposure might seem prudent for any individual whose test results suggest heightened disease risk, we will argue that such a clinical precautionary approach is likely to be a mistake. Instead, advice on the interpretation of screening results must focus not on risk per se, but on avoidable risk, and must be carefully tailored to the individual. These points are of importance for individual decision-making, for informed consent, and for occupational health.

Entities:  

Mesh:

Year:  2008        PMID: 19058029     DOI: 10.1007/s11017-008-9087-8

Source DB:  PubMed          Journal:  Theor Med Bioeth        ISSN: 1386-7415


  7 in total

1.  A model for optimization of biomarker testing frequency to minimize disease and cost: example of beryllium sensitization testing.

Authors:  Nancy L Judd; William C Griffith; Tim Takaro; Elaine M Faustman
Journal:  Risk Anal       Date:  2003-12       Impact factor: 4.000

Review 2.  Use of beryllium lymphocyte proliferation testing for screening of asymptomatic individuals: an evidence-based assessment.

Authors:  Jonathan Borak; Steven H Woolf; Cheryl A Fields
Journal:  J Occup Environ Med       Date:  2006-09       Impact factor: 2.162

3.  Screening blood test identifies subclinical beryllium disease.

Authors:  K Kreiss; L S Newman; M M Mroz; P A Campbell
Journal:  J Occup Med       Date:  1989-07

Review 4.  [Chronic beryllium disease: a model of interaction between environmental exposure and genetic predisposition. Pathogenesis and clinical features (Part 2)].

Authors:  S Marchand-Adam; F Guillon; M Brauner; D Valeyre
Journal:  Rev Mal Respir       Date:  2005-04       Impact factor: 0.622

5.  Chronic beryllium disease and beryllium sensitization at Rocky Flats: a case-control study.

Authors:  S M Viet; J Torma-Krajewski; J Rogers
Journal:  AIHAJ       Date:  2000 Mar-Apr

6.  Beryllium sensitization progresses to chronic beryllium disease: a longitudinal study of disease risk.

Authors:  Lee S Newman; Margaret M Mroz; Ronald Balkissoon; Lisa A Maier
Journal:  Am J Respir Crit Care Med       Date:  2004-09-16       Impact factor: 21.405

7.  Chronic beryllium disease and sensitization at a beryllium processing facility.

Authors:  Kenneth Rosenman; Vicki Hertzberg; Carol Rice; Mary Jo Reilly; Judith Aronchick; John E Parker; Jackie Regovich; Milton Rossman
Journal:  Environ Health Perspect       Date:  2005-10       Impact factor: 9.031

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.